Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
NCT00006734
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy an... Read More
Gender:
ALL
Ages:
Between 0 years and 50 years
Trial Updated:
08/01/2023
Locations: Southern California Permanente Medical Group, Downey, California +21 locations
Conditions: Sarcoma
Register for Updates
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT05266196
Enrolling By Invitation
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/31/2023
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Myoepithelial Tumor, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
Register for Updates
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
NCT01614197
Completed
This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma (PTL).
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/25/2023
Locations: Childrens Hospital Los Angeles, Los Angeles, California +2 locations
Conditions: Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Register for Updates
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
NCT04314843
Terminated
The primary objectives of this study are: Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most appropriate dose of lenzilumab for Phase 2. Phase 2: To evaluate the incidence of neurologic events with sequenced therapy given at the recommended Phase 2 dose (RP2D) of lenzilumab in participants with relapsed or refractory large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Stanford University, Palo Alto, California
Conditions: Relapsed/Refractory Large B-cell Lymphoma
Register for Updates
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05244070
Terminated
The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Local Institution - 0016, Duarte, California
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma
Register for Updates
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
NCT05508009
Recruiting
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the risk of chronic rejection and, ultimately, the need for repeated transplantation.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/13/2023
Locations: Lucile Packard Children's Hospital, Palo Alto, California
Conditions: SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Register for Updates
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, amifostine, and peripheral stem cell transplantation in treating pat... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
07/03/2023
Locations: Cancer Center and Beckman Research Institute, City of Hope, Duarte, California
Conditions: Breast Cancer
Register for Updates
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00828009
Completed
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Veterans Affairs Medical Center - Palo Alto, Palo Alto, California +1 locations
Conditions: Lung Cancer
Register for Updates
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
NCT00005962
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining more than one drug or combining monoclonal antibody with chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia. PURP... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/20/2023
Locations: Cancer Center and Beckman Research Institute, City of Hope, Duarte, California +2 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
NCT00003388
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in treating patients with AIDS-related lymphoma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/20/2023
Locations: Veterans Affairs Medical Center - Palo Alto, Palo Alto, California +1 locations
Conditions: Lymphoma
Register for Updates
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00274924
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/15/2023
Locations: Veterans Affairs Medical Center - Palo Alto, Palo Alto, California
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00003389
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/14/2023
Locations: Alta Bates Comprehensive Cancer Center, Berkeley, California +40 locations
Conditions: Lymphoma
Register for Updates